A Phase III GO2 randomized trial has compared treatment for 514 older and frail people with advanced gastroesophageal cancer, the findings will be presented at the 2019 ASCO Annual Meeting (31 May – 4 June 2019, IL, USA).
To view the full article, please register now for access